Reduction of Genotoxicity of Carbamazepine to Human Lymphocytes by Pre-treatment with Vitamin B12

Curr Mol Pharmacol. 2023;16(2):228-233. doi: 10.2174/1874467215666220420135924.

Abstract

Background: Carbamazepine (CBZ) is widely used as an anti-epileptic drug. Vitamin B12 has been shown to protect against DNA damage caused by several mutagenic agents.

Objective: This study aimed to investigate the effect of vitamin B12 on CBZ-induced genotoxicity in cultured human lymphocytes.

Methods: Sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) genotoxic assays were utilized to achieve the study objective.

Results: The results showed significantly higher frequencies of CAs and SCEs in the CBZ-treated cultures (12 μg/mL) compared to the control group (P<0.01). The genotoxic effects of CBZ were reduced by pre-treatment of cultures with vitamin B12 (13.5μg/ml, P<0.05). Neither CBZ nor vitamin B-12 showed any effects on mitotic and proliferative indices.

Conclusion: CBZ is genotoxic to lymphocyte cells, and this genotoxicity can be reduced by vitamin B12.

Keywords: Carbamazepine; DNA damage; chromosomal aberrations; genotoxicity; sister chromatid exchanges; vitamin B12; white lymphocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzodiazepines
  • Carbamazepine / toxicity
  • Chromosome Aberrations*
  • DNA Damage
  • Humans
  • Lymphocytes
  • Vitamin B 12* / pharmacology

Substances

  • Vitamin B 12
  • Carbamazepine
  • Benzodiazepines